CIPLA.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally...

Stats
Šios dienos apimtis	694 955
Vidutinė apimtis	1.56M
Rinkos kapitalizacija	1 137.70B
EPS	INR13.07 ( 2024-01-24 )
Kita pelno data	( INR10.73 ) 2024-05-09
Last Dividend	INR8.50 ( 2023-07-20 )
Next Dividend	INR0 ( N/A )
P/E	30.67
ATR14	INR1.295 (0.09%)

Tūris Koreliacija

Ilgas: -0.05 (neutral)

Trumpas: 0.09 (neutral)

Signal:(47.458) Neutral

Cipla Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
NESCO.NS	0.972
SPENTEX.NS	0.97
PODDARHOUS.NS	0.967
HONAUT.NS	0.965
INSECTICID.NS	0.963
SHAILY.NS	0.962
JINDALPOLY.NS	0.96
AWHCL.NS	0.957
ESTER.NS	0.957
SETUINFRA.NS	0.957

10 Labiausiai neigiamai susiję koreliacijos
KIRLFER.NS	-0.948
JSLHISAR.NS	-0.937
CIGNITITEC.NS	-0.933
JINDALSAW.NS	-0.931
PGEL.NS	-0.925
SONATSOFTW.NS	-0.919
KAYNES.NS	-0.918
OIL.NS	-0.918
ISMTLTD.NS	-0.917
CLSEL.NS	-0.916

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Cipla Limited Koreliacija - Valiuta/Žaliavos

0.20
( neutral )

0.04
( neutral )

-0.20
( neutral )

0.24
( neutral )

0.35
( neutral )

0.20
( neutral )

Cipla Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR224.73B
Bruto pelnas:	INR142.21B (63.28 %)
EPS:	INR34.72

FY	2022
Pajamos:	INR224.73B
Bruto pelnas:	INR142.21B (63.28 %)
EPS:	INR34.72

FY	2022
Pajamos:	INR216.33B
Bruto pelnas:	INR124.03B (57.33 %)
EPS:	INR31.20

FY	2021
Pajamos:	INR190.23B
Bruto pelnas:	INR110.03B (57.84 %)
EPS:	INR29.82

Financial Reports:

No articles found.

Cipla Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR8.50 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Cipla Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.06 - low (2.05%) | Divividend Growth Potential Score: 3.02 - Decrease likely (39.54%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.0933	1997-07-28
Last Dividend	INR8.50	2023-07-20
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	28	--
Total Paid Out	INR55.50	--
Avg. Dividend % Per Year	0.41%	--
Score	1.86	--
Div. Sustainability Score	3.06
Div.Growth Potential Score	3.02
Div. Directional Score	3.04	--

Next Divdend (Est)
(2024-07-01)

INR9.30 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.86

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR3.00	0.51%
2019	INR3.00	0.57%
2020	INR1.000	0.21%
2021	INR5.00	0.61%
2022	INR5.00	0.54%
2023	INR8.50	0.79%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
UBL.NS	Dividend Junior	2023-08-03	Annually	17	0.27%
POLYCAB.NS	Dividend Knight	2023-06-21	Annually	6	0.50%
JSL.NS	Dividend Junior	2023-09-15	Sporadic	22	0.26%
DLF.NS	Dividend Junior	2023-07-28	Annually	18	0.60%
AARON.NS	Dividend Junior	2023-08-28	Sporadic	5	0.36%
SOUTHBANK.NS	Dividend Junior	2023-08-17	Sporadic	25	0.42%
MONARCH.NS	Dividend Junior	2023-09-14	Annually	3	0.20%
HERANBA.NS	Dividend Junior	2023-08-17	Annually	4	0.20%
BHEL.NS	Dividend Junior	2023-08-11	Annually	21	0.26%
RAMCOIND.NS	Dividend Junior	2023-08-02	Annually	23	0.32%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.148	1.500	7.04	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.153	1.500	9.41	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	51.90	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	19.38	2.00	3.54	7.08	[0 - 30]
freeCashFlowPerShareTTM	19.38	2.00	0.312	0.623	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.647	1.000	2.55	2.55	[0.2 - 0.8]
operatingProfitMarginTTM	0.221	1.000	7.58	7.58	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.06

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	30.68	1.000	7.00	0	[1 - 100]
returnOnEquityTTM	0.153	2.50	9.62	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	19.38	2.00	3.54	0.623	[0 - 30]
dividendYielPercentageTTM	0.603	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	19.38	2.00	3.54	7.08	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-3.05	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0625	1.000	-0.937	0	[0.1 - 0.5]
Total Score				3.02

Cipla Limited

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.